Acne Treatment Plan: Dusa Pharmaceuticals

dusa pharmaceuticals

Mumbai: Sun Pharmaceuticals Industries Ltd, India’s most valuable drug maker, has agreed to buy US-based skincare speciality company dusa pharmaceuticals Inc. for $230 million (Rs.1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma NEW YORK ( TheStreet) -- dusa pharmaceuticals (Nasdaq: DUSA) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with New Delhi: Drug firm Sun Pharmaceutical Industries Thursday said its US-based subsidiary Caraco has successfully completed the tender offer to acquire dusa pharmaceuticals. The company said after the tender offer's expiration, 2,09,46,624 shares of common Sun Pharmaceutical Industries Limited and DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its DUSA Pharmaceuticals INVESTOR ALERT: Briscoe Law Firm and Powers Taylor, LLP Investigate Sale to Sun Pharma DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Sun Pharmaceutical Industries Limited and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its 'Levulan' photodynamic therapy platform. .

Sun Pharmaceutical Industries Limited and DUSA Pharmaceuticals, Inc. have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl MUMBAI: Sun Pharma announced on Thursday it will acquire US-based dermatology company DUSA Pharmaceuticals, Inc for $230 million. The company is focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of DUSA Pharmaceuticals, Inc. (“DUSA”) (Nasdaq GM: DUSA) to Sun Pharmaceuticals DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and .